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http://www.biomedcentral.com/1471-2164/14/867RESEARCH ARTICLE Open AccessAssociation of homocysteine with type 2 diabetes:
a meta-analysis implementing Mendelian
randomization approach
Tao Huang1,2,3, JingJing Ren4, Jinyan Huang5 and Duo Li2,3*Abstract
Background: We tested the hypothesis that elevated homocysteine (Hcy) level is causally associated with increased
risk of type 2 diabetes mellitus (T2DM).
Results: The meta-analysis and Mendelian randomization analysis were performed among 4011 cases and 4303
controls. The absolute pooled mean Hcy concentration in subjects with MTHFR 677TT was 5.55 μmol/L (95% CI,
1.33 to 9.77) greater than that in subjects with MTHFR 677CC in T2DM. Overall, the T allele of the MTHFR 677 C > T
conferred a greater risk for T2DM [Random effect (RE) OR = 1.31(1.17-1.64), I2 = 41.0%, p = 0.055]. The random effect
(RE) pooled OR associated with T2DM for MTHFR 677TT relative to the 677CC was [RE OR = 1.38(1.18-1.62)]. The
fixed-effect pooled OR of the association for the MTHFR 677 TT vs CT was 1.29 (95% CI, 1.09-1.51). MTHFR 677 TT
showed a significantly higher risk for T2DM compared with MTHFR 677 CC + CT [Fixed effect (FE) OR = 1.32(1.14-1.54),
I2 = 0.0%, p = 0.686]. The absolute pooled mean Hcy concentration in individuals with T2DM was 0.94 μmol/L (95% CI,
0.40-1.48) greater than that in control subjects. The estimated causal OR associated with T2DM was 1.29 for 5 μmol/L
increment in Hcy.
Conclusions: Our findings provided strong evidence on the causal association of Hcy level with the development
of T2DM.
Keywords: Homocysteine, MTHFR, Type 2 diabetesBackground
The pathophysiology of type 2 diabetes mellitus (T2DM)
characterized by a high incidence of vascular complica-
tions is complex and multifactorial [1]. The major cause
of T2DM and its complications has not yet been clari-
fied. In recent years, plasma homocysteine (Hcy) level, a
sulphur-containing non-protein amino acid in the me-
tabolism of methionine, has been reported to be associ-
ated with the vascular complications of diabetes [2]. In
patients with diabetes, elevated Hcy levels were associ-
ated with insulin resistance [3] and nephropathy [4]. Of
note, several studies have demonstrated that elevated
Hcy levels predict the risk of death or coronary events in
patients with T2DM [5,6]. However, conflicting results* Correspondence: duoli@zju.edu.cn
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reproduction in any medium, provided the orregarding the Hcy level in patients with diabetes have
been reported. Some studies found that plasma Hcy
levels were increased [7,8], unchanged [9-11], or decreased
[12,13] in patients with T2DM.
The candidate gene approach is widely used for identi-
fying genes involved in complex human diseases [14].
5,10 methylene-tetrahydrofolate reductase (MTHFR) is
the key rate-limiting enzyme required for the conversion
of dietary folate to 5-methyltetrahydrofolate, the methyl
group donor required for the remethylation of Hcy to
methionine in vivo [15]. Hyperhomocysteinemia (HHcy)
may be due to the presence of a thermolabile isoform of
this key enzyme. A single base pair (677C > T) substitution
in the human MTHFR gene predicts phenotypic expres-
sion of a heat-sensitive variant with reduced enzymatic ac-
tivity [16]. Elevated Hcy level caused by MTHFR genetic
variants has been demonstrated to be associated with insu-
lin resistance [17-19]. Hcy exerts detrimental effects on a
number of cell lineages including endothelial cells andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cies (ROS) [20]. Both acute and prolonged exposure to
Hcy had detrimental effects on beta cell glucose metabol-
ism, insulin secretory responsiveness and cell viability
[20,21]. Hcy generates ROS in a redox-cycling reaction that
explains the decline in viability of insulin-secreting cells,
leading to reduced glucokinase phosphorylating ability,
diminished insulin secretory responsiveness and cell death
[22]. Based on its biological functions, this variant has been
considered an ideal candidate for genetic polymorphism
for predisposition to diabetes [23], as it is common in
many populations studied to date and the genotype corre-
lates highly with the plasma Hcy level in a dose-dependent
fashion [24].
In recent years, there have been a number of case–
control studies investigating the association between the
677 C > T polymorphism in the MTHFR gene and T2DM
or diabetes-related complications [12,16,25-40]. However,
these studies have reported conflicting results, which
has prevented a definitive conclusion to date. The as-
sociations of Hcy, MTHFR polymorphism and T2DM
are still inconclusive.
To provide an answer to these contradictory results
and elucidate the possible mechanism, a meta-analysis of
the published literature regarding the risk for T2DM as-
sociated with an elevated Hcy level and the MTHFR
677C > T was conducted. In this meta-analysis, the esti-
mate of the genetic association of each individual study
and a pooled estimate of this association were obtained.
Furthermore, to test the hypothesis that elevated Hcy is
causally related to increased risk of T2DM, Mendelian
randomization analysis, which is an epidemiological ap-
proach based on the fact that individuals inherit genetic
variants randomly from their parents, was conducted.
Methods
Selection of studies
All studies that investigated the association of the 677 C
> T polymorphism in the MTHFR gene and Hcy with
the development of diabetes were considered in this
meta-analysis. We searched the following electronic da-
tabases from inception to December 2012: PubMed and
web of science databases. As a search criterion, we used
the following terms: “MTHFR”, “MTHFR 677”, “homo-
cysteine”, “Hcy”, “diabetes”, “type 2 diabetes”, “T2DM”,
and “polymorphism”.
The retrieved publications were then read in their
entirety in order to assess their appropriateness for in-
clusion in this meta-analysis. All references cited in the
studies were also reviewed to identify additional pub-
lished work not indexed by PubMed and web of science
databases. Case–control studies that determined the dis-
tribution of the MTFHR 677 C > T genotypes in diabetes
and in controls free of diabetes were eligible for inclusion.Abstracts, editorials, and review articles were excluded.
The search was restricted to articles in English.
Data extraction
Data was carefully extracted from all eligible studies in-
dependently by two investigators, and an agreement was
reached on all items after discussion with a third investi-
gator. The following information was collected from
each study: (1) first author's surname, publication date,
subjects’ country and ethnicity; and (2) total number,
definition and characteristics of cases and controls, and
distribution of genotypes and alleles in all groups. For
those studies that included subjects of different ethnic
groups, data was extracted separately for each of the eth-
nic groups.
Data analysis and statistical methods
Hardy-Weinberg equilibrium (HWE) using chi-square
test was tested to in control group to determine whether
it is in. Studies with controls not in HWE were subjected
to a sensitivity analysis.
The meta-analysis examined the overall association of
MTHFR 677C > T and risk of diabetes; and the contrast
of homozygotes TT versus CC, the contrast TT versus
(TC + CC), and the contrast (TT + TC) versus CC. All
associations were indicated as odds ratios (OR) with the
corresponding 95% confidence interval (CI). Then, based
on the individual OR, a pooled OR was estimated. We
used Stata Commands metan to estimate the mean
differences for the comparisons of MTHFR 677 TT versus
MTHFR 677 CC and for the comparisons of subjects with
T2DM versus healthy subjects. To incorporate both within-
study and between-study variability, we used random-
effects model to calculate the standardized mean difference
and 95% CI to pool the results for Hcy.
Heterogeneity between studies was tested using the
Q-statistic, which is a weighted sum of squares of the
deviations of individual study OR estimates from the
overall estimate [16]. When the OR were homogeneous,
Q follows a chi-squared distribution with r-1 (r is the
number of studies) degrees of freedom (df). If p < 0. 05,
then the heterogeneity was considered statistically sig-
nificant. Heterogeneity was quantified with the I2 metric
(I2 = (Q-df)/Q), which is independent of the number of
studies in the meta-analysis [41]. The I2 takes values
between 0% and 100%, with higher values denoting greater
degree of heterogeneity (I2 = 0-25%, no heterogeneity; I2 =
25-50%, moderate heterogeneity; I2 = 50-75%, large hetero-
geneity; I2 = 75-100%, extreme heterogeneity). The pooled
OR was estimated using fixed effects (Mantel-Haenszel)
and random effects models. A random effect model as-
sumes a genuine diversity in the results of various studies,
and it incorporates into the calculations a between-study
variance. Therefore, when there is heterogeneity between
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effects model [16].
The meta-analysis consisted of the main analysis,
which includes all available data; the sub-group analysis
of ethnic groups. Begg’s funnel plot and Egger’s regres-
sion test (significant at p < 0.05) were used to evaluate
publication bias. Extracted data was analyzed using the
Stata, version 11 software (StataCorp, College Station,
TX, USA).
Mendelian randomization analysis is based on the con-
cept of Mendelian randomization, that is, the fact that one’s
genes are inherited before birth by a seemingly random
process analogous to treatment allocation in a randomized
trial. The Mendelian randomization analysis incorporating
information on both the genotype-intermediate phenotype
association and genotype-disease association into one
analytical framework may allow for an unbiased esti-
mate of the intermediate phenotype-disease association.
In the Mendelian randomization paradigm, an instrumen-
tal variable has to satisfy the following three criteria [42,43]:
1) theMTHFR 677C >T should be robustly associated with
Hcy; 2) the genotype should not be associated with
confounding factors that bias the association between
intermediate Hcy and T2DM; 3) absence of plei-
otropy, as the MTHFR 677C > T should exert its effect
on the T2DM only through the specific intermediate
Hcy. Based on available evidence, MTHFR 677C > T
seemed to meet these assumptions well [6,39,44,45]. Thus,
the Mendelian randomization coefficient estimates using
MTHFR 677C > T as instruments would provide the
causal association between Hcy and T2DM risk free of
bias due to reverse causation and residual confounding.
Suppose that the mutant genotype of MTHFR 677 C > T
(TT) is associated with an increased risk of T2DM com-
pared to the wildtype (CC) and that this effect is measured
by its odd ratio (ORTT vs CC). Further suppose that TT is
associated with a mean difference (Δ) in the level of Hcy
compared with CC. OR1 = (ORTT vs CC)
1/Δ is an uncon-
founded estimate of the OR of T2DM resulting from a
unit change in the Hcy. It may be more informative to re-
scale this OR for increments other than a unit change in
Hcy. For an increment of k units the formula becomes
ORk = (ORTT vs CC)
k/Δ[46], in this analysis, we used
5 μmol/l increase in serum Hcy to calculate the OR [47].
Results
Summary statistics
The seventeen studies provided 4011 cases and 4303
controls [12,25-40] (Figure 1). The allele C was the most
common. The frequencies of the CC genotype were the
highest in controls and in cases, while that for genotype
TT was the lowest. Three studies only reported the asso-
ciation between blood Hcy level and MTHFR 677 C > T
in diabetes patients [48-50]. In three studies [34-36], thedistribution of the genotypes in the control group was
not in HWE (p < 0.05) (Table 1).
Pooled difference in mean Hcy level between MTHFR
genotypes in type 2 diabetes patients
Eleven studies (2498 T2DM) [12,25,30,31,35,38,39,48-50]
were identified that satisfied inclusion criteria and
expressed the between-group difference in plasma Hcy
level in terms of the arithmetic mean and standard devi-
ation. In all these studies, the mean Hcy concentration
was greater in subjects with MTHFR 677TT than in those
with the other two genotypes. The absolute pooled mean
Hcy concentration in subjects with MTHFR 677TT was
5.55 μmol/L (95% CI, 1.33 to 9.77) greater than that in
subjects with MTHFR 677CC (p = 0.012) (Figure 2).
While, the subjects with MTHFR 677TT had 4.06 μmol/L
higher Hcy concentration than subjects with MTHFR
677CT (p = 0.008) (Figure 3). The sensitivity analysis re-
garding the MTHFR 677C > T not being in HWE did not
significant change the results.
The association between MTHFR 677 C > T and risk of
type 2 diabetes
The main analysis for investigating the association be-
tween MTHFR 677TT and risk of developing T2DM
relative to the 677CC revealed significant heterogeneity
(p for heterogeneity = 0.035, I2 = 43%) between 17 stud-
ies; the random effect (RE) pooled OR was significant:
RE OR = 1.33 (1.05-1.67) (p = 0.021) (Figure 4). Overall,
the T allele of the MTHFR 677 C > T conferred a greater
risk for T2DM [RE OR = 1.31(1.05-1.64) (p = 0.032), I2 =
41.0%, p for heterogeneity =0.055] (Figure 5). The
random-effect pooled OR of the association for MTHFR
677 TT vs CT was 1.29 (95% CI, 1.09-1.51) (p = 0.021).
MTHFR 677 TT showed a significantly higher risk for
T2DM compared with MTHFR 677 CC + CT [Fixed
effect (FE) OR = 1.32(1.14-1.54) (p = 0.034), I2 = 0.0%,
p for heterogeneity =0.686]. MTHFR 677 TT + CT also
showed a significantly higher risk for T2DM compared
with MTHFR 677 CC [RE OR = 1.12 (1.07-1.34) (p =
0.029), I2 = 42.0%, p for heterogeneity =0.046]. Subgroup
analysis was also performed to ensure that the application
of the method of estimating the causal effect is unbiased.
Subgroup analysis was grouped by studies that reported
results on both associations (MTHFR 677 C > T-T2DM ef-
fects and MTHFR 677 C > T-Hcy effects) and by those re-
ported only a single association result. The results showed
similar significant effect sizes between both groups (both:
1.44 (0.93-2.23), Single: 1.35 (1.03-1.75).
The associations between plasma Hcy and type 2
diabetes
Figure 6 showed a forest plot of standardized mean
difference (SMD) in Hcy between subjects with and
Figure 1 PRISMA flow diagram for selection of studies in the meta-analysis.
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for this association revealed significant heterogeneity
(p for heterogeneity < 0.001, I2 = 98.0%) between the stud-
ies. In 14 of these studies [7,8,12,13,25,30,33,35,40,51-54],
the mean Hcy concentration was greater in patients with
T2DM than in control subjects (Figure 6). The absolute
pooled mean Hcy concentration in patients with T2DM
was 0.94 μmol/L (95% CI, 0.40-1.48) greater than that in
control subjects in random model (p = 0.017). We further
conducted a subgroup analysis of ethnic groups, all results
from Europe, Asia and Africa showed significant differ-
ences in Hcy levels between subjects with or without
T2DM. Additionally, subgroup analysis was also grouped
by studies that reported results on both associations
(MTHFR 677 C > T-T2DM effects andMTHFR 677 C > T-
Hcy effects) and by those reported only a single associ-
ation result. The results showed similar significant effect
sizes between both groups (both: 5.94 (0.30-11.59), Single:
3.03 (−0.02-6.08). In addition, Begg’s and Egger’s tests
did not show evidence for the presence of substantialpublication bias for the Hcy-T2DM association in dif-
ferent inheritance models (data not shown).
Causal association of Hcy with risk of type 2 diabetes by
Mendelian randomization
Figure 7 showed the predicted OR of T2DM associated
with per unit increase in direct or indirect measures of
Hcy using MTHFR 677 C > T as an instrumental variable
for Hcy. Increased Hcy levels were strongly associated with
increased risk of type 2 diabetes. The estimated causal OR
for 5 μmol/L Hcy increment was 1.29 (1.04-1.59).
Discussions
Overall, we found that MTHFR 677 T was significantly
associated with elevated plasma Hcy concentration. The
pooled mean Hcy concentration was greater in subjects
with T2DM than in those without T2DM. Our findings
from Mendelian randomization approach supported the
hypothesis that elevated Hcy is causally related to in-
creased risk of T2DM.
Table 1 The distribution of the MTHFR 677 C > T genotype for case and control and the allele frequencies
First author Year Ethnical
decent
Distribution of MTHFR genotypes (n(%)) Frequency of MTHFR alleles (%) P-valueHWE
CC CT TT C T
Case Control Case Control Case Control Case Control Case Control
Ndrepepa et al. [25] 2008 Germany 225(44) 690(43) 215(42) 740(46) 67(13) 184(11) / / / / 0.49
Mazza et al. [12] 2005 Italy 35(33) 35(29) 47(45) 66(55) 23(22) 19(16) / / / / 0.19
Bluthner et al. [26] 1999 Poland 137(47) 67(45) 115(39) 68(45) 41(13) 15(10) / 67 / 33 0.71
Benes et al. [27] 2001 Czech 166(48) 86(41) 152(43) 106(51) 31(8) 17(8) 69 67 31 33 0.05
Yilmaz et al. [28] 2004 Turkish 121(49) 101(47) 98(39) 93(44) 30(12) 20(9) 68 69 32 31 0.83
Eroglu et al. [29] 2007 Turkish 51(50) 63(49) 45(44) 58(45) 7(7) 7(6) 71 71 29 29 0.17
Tutuncu et al. [30] 2005 Turkey 41(45) 52(52) 39(43) 43(43) 11(12) 5(5) 60 70 40 30 0.29
Soares et al. [31] 2007 UK 10(55) 9(56) 6(33) 5(31) 2(11) 2(13) / / / / 0.36
Angeline et al. [32] 2009 Indian 88(73) 80(80) 32(27) 20(20) 0 0 88 90 12 10 0.57
Mehri et al. [33] 2010 Tunisian 50(43) 66(57) 49(43) 38(33) 16(14) 12(10) 65 73 35 27 0.07
Sun et al. [34] 2004 Chinese 102(46) 74(57) 76(35) 34(26) 42(19) 22(17) 64 70 56 30 0.001
Mtiraoui et al. [35] 2007 Tunisia 163(45) 270(68) 135(38) 94(24) 62(17) 36(9) 64 79 36 21 0
Sun et al. [36] 2003 Chinese 84(40) 31(54) 75(36) 16(28) 49(24) 10(18) 58 68 42 32 0.01
Movva, et al. [37] 2011 Indian 68(68) 91(91) 32(32) 9(9) 0 0 84 95 16 4 0.05
Tavakkoly
Bazzaz et al. [38]
2010 Iran 148(53) 113(55) 102(36) 80(39) 31(11) 14(7) 71 76 26 24 0.21
Benrahma et al. [39] 2012 Morocco 160(57) 114(44) 97(35) 122(47) 25(9) 26(10) 74 67 26 33 0.19
Sharaf et al. [40] 2012 Egypt 24(48) 13(65) 17(34) 5(25) 9(18) 2(10) 65 78 35 22 0.13
The significance level (p-value) for Hardy-Weinberg equilibrium (HWE) testing for controls is shown.
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ing the circulating Hcy levels in patients with diabetes.
An association between Hcy level and diabetic complica-
tions was seen in type I diabetes, but not among T2DM
[7]. Very recently, a study on 105 patients with T2DM
and normal renal function also found that in patients
with T2DM, basal level of Hcy was 35% lower compared
with healthy subjects [12]. The reduced Hcy level may
be explained by an influence of hyperglycemia on accel-
eration in the hepatic transsulfuration pathway due to
insulin disorder [12], subsequently, elevated glucocorti-
coids decreased Hcy level [55]. Cell culture and animal
studies also showed that the diabetic status may reduce
rather than increase the circulating Hcy level due to en-
hanced Hcy catabolism [55,56]. However, it should be
emphasized that this data was derived from animal
models of experimental diabetes and cannot provide
solid evidence that a similar relationship between dia-
betic status and Hcy level exists in patients with dia-
betes. Moreover, many other studies found that plasma
Hcy levels were significantly higher in diabetic patients
than in subjects without diabetes. In the present meta-
analysis, the main analysis for weighted mean difference
in Hcy between subjects with and without T2DM in all
included studies revealed significant heterogeneity be-
tween the studies. Therefore, we used random model to
estimate the pooled mean Hcy. Similarly, the absolutepooled mean Hcy concentration in individuals with
T2DM was also significantly higher than that in control
subjects in random model. We speculated that a large
part of the discrepancy resulted from the heterogeneity
of patients included in these studies with regard to the
stage of disease, status of renal function or presence of
macroangiopathy [4,9]. Furthermore, the opposing influ-
ences on circulating Hcy levels exercised by the diabetic
status per se and by a number of risk factors that relate
to or are accentuated by diabetes may also help explain
the controversy [25].
Importantly, the heterogeneity may also result from
the genetic background of the patients. A common vari-
ant (MTHFR 677 C > T) of the enzyme MTHFR involved
in the Hcy metabolic pathway may affect Hcy concentra-
tion [57]. Among the diabetic group, patients carrying
the T allele showed a increased Hcy level in comparison
to those having the native genotype CC [23]. This con-
tradicted a previous report which suggested that double
heterozygosity was associated with reduced enzyme ac-
tivity and high Hcy level [58]. Interestingly, the MTHFR
677 C > T appears to have a sex-specific effect on Hcy,
Hcy level was slightly higher in men than in women
[59]. Men carrying TT genotype appear to be at higher risk
of HHcy than women with this genotype [60]. Plasma es-
trogen was found to decrease in MTHFR CC, but not in
TT homozygous postmenopausal women [61]. The precise
Figure 2 Summary estimates for the effect size (ES) in plasma Hcy between the MTHFR genotypes (TT vs CC) in type 2 diabetes
patients. aT2DM patients with nephropathy, bT2DM patients without nephropathy.
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ism is not known. But the sex-specific effect may contrib-
ute to the previous contradicted results. Our meta-analysis
gave strong evidence that the MTHFR was associated with
plasma Hcy in patients with T2DM. MTHFR 677TT have
significantly higher plasma Hcy than other genotypes,
which are consistent with previous results in diabetic sub-
jects [25].Figure 3 Summary estimates for the effect size (ES) in plasma Hcy be
patients. aT2DM patients with nephropathy, bT2DM patients without nephBecause elevated plasma Hcy level in patients with
T2DM has been reported, it may be readily postulated
that the 677 C > T MTHFR gene polymorphism might
be involved in the development of T2DM [23]. However,
no literature data directly associates the MTHFR-linked
Hcy metabolism with T2DM. To date, the relationship be-
tween theMTHFR 677 C > T polymorphism and T2DM is
less clear. Previous studies found an association betweentween the MTHFR genotypes (TT vs CT) in type 2 diabetes
ropathy.
Figure 4 Summary estimates for the OR of MTHFR 677 C > T in genotype contrasts (TT vs CC), the OR with the 95% confidence interval
is shown. Studies are displayed by descending order of publication year.
Huang et al. BMC Genomics 2013, 14:867 Page 7 of 11
http://www.biomedcentral.com/1471-2164/14/867mutant homozygous genotype for MTHFR 677 C > T and
diabetic retinopathy in individuals with T2DM [62]. Simi-
larly, another study has also found that theMTHFR 677 C
> T predisposes T2DM patients to the development of dia-
betic retinopathy [63]. One study suggested the MTHFR
mutant genotype as a possible risk factor for the develop-
ment of left ventricular hypertrophy in T2DM [28]. The
TT genotype was more frequent in T2DM patients than inFigure 5 Summary estimates for the OR of MTHFR 677 C > T in allele
shown. Studies are displayed by descending order of publication year.healthy controls (13.9% vs. 10.3%). Of interest is that the
Brazilian population holds the lowest frequency ever re-
ported for the TT genotype (9%) [53], and the highest
(19.1%) is in Chinese population [34]. In fact, the associ-
ation between theMTHFR 677 C >T and diabetes was not
found in some studies including Brazil [53], China [34],
Germany [25]. The reasons why there are conflicting re-
sults in studies concerning MTHFR677 C >T and T2DMcontrasts (T vs C), the OR with the 95% confidence interval is
Figure 6 Forest plot of standardized mean difference (SMD) in Hcy between subjects with and without type 2 diabetes in included
studies. aT2DM patients with nephropathy, bT2DM patients without nephropathy.
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for conflicting results may relate to the different gen-
etic background of patients included in the studies.
The frequency of MTHFR 677TT varies in different eth-
nic groups, for example, the 677TT genotype frequency
is the lowest in Moroccan patients and controls (8.87%
and 9.92%, respectively) [39]. Similarly, low frequency of
677TT (9%) was also reported in a Brazilian population
[53]. In contrast, a high frequency (19.1%) of the 677TT
genotype was reported in a Chinese population [34]. Fur-
thermore, small sample size, study design flaws or other
biases may be more common reasons than true racial het-
erogeneity for the observed discrepancies between studiesFigure 7 The potential causal relation between Hcy and T2DM
risk was explored by using Mendelian randomization.
Calculation of an unconfounded estimate of the effect of an
increase in Hcy of 1 μmol/L on the risk of T2DM based on the
concept of Mendelian randomization.addressing genetic risks [64,65]. The meta-analysis pre-
sented here included data from case–control association
studies that investigated the relationship between MTHFR
polymorphism and T2DM. The strength of the present
analysis, however, is based on the aggregation of published
case–control studies. The overall results indicated an as-
sociation of MTHFR 677 C > T with T2DM and MTHFR
TT genotype increases the risk of T2DM.
Our study is the first meta-analysis to date which has
pooled all the data available to investigate the associa-
tions of MTHFR-linked Hcy and T2DM. Therefore we
have provided the most extensive data on this issue. As
with all meta-analyses, some limitations are also pre-
sented here. First, the lack of clinical homogeneity be-
tween the subjects in the included studies, although our
inclusion criteria ensured that the selected studies were
broadly similar, it was not possible to eliminate all sources
of heterogeneity. Second, we pooled the data from differ-
ent ethnicities together, genetic heterogeneity among di-
verse ethnic populations leads to some unavoidable bias.
Third, many studies did not include information regarding
vitamin status at the time of Hcy measurement, which
prevented examination of the interaction between nutri-
tional status, Hcy, genotypes, and diabetic risk. Differences
in sampling protocols and methods of Hcy measurement
may have contributed to variation between studies. Hcy
measurement using different high-performance liquid
chromatography methods has been reported to vary by 6
to 7% among different laboratories [66]. Fourthly, exclu-
sion of studies which didn’t provide adequate information
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exclude the possibility of bias related to the exclusion of
non-English language publications, although Begg’s and
Egger’s tests did not show evidence for the presence of
substantial publication bias with respect to the small effect
sizes. Fifthly, although we observed elevated Hcy is caus-
ally related to increased risk of T2DM, recent clinical trial
showed that lowering Hcy levels by daily supplementation
with folic acid and vitamins B6 and B12 did not reduce the
risk of developing T2D among women at high risk for
CVD [67]. We specialated that the associations of Hcy
with T2D may be modified by environmental factors such
as dietary folate, as well as the potential gene-environment
interactions involved in the development of T2D. Finally,
the association of the MTHFR variant with T2D was not
observed in large-scale GWAS studies with huge sample
sizes. The possible reason is that this association is likely to
be due to the combined effect of genes, environmental fac-
tors, and their interactions. However, most investigators
conducting GWAS do not consider gene-environment in-
teractions in their search for new genes due to a current
lack of efficient statistical methods for detecting interac-
tions in high-volume genetic data.
Conclusions
In summary, our results provided evidence that the TT
genotype of MTHFR C677T contributes to susceptibility
to T2DM, and supported the hypothesis that elevated
Hcy is causally related to increased risk of T2DM. The
existence of gene-environment interactions may explain
the discrepancy of results obtained in individual genetic
association studies. Therefore, case–control studies that
investigate gene-environment interactions might help
further elucidate the genetics of T2DM.
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